Please ensure Javascript is enabled for purposes of website accessibility

Here's Why Incyte Stock Tumbled 16.3% in January

By Maxx Chatsko - Feb 7, 2020 at 3:12PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

A failed study disappointed investors, but the company's pipeline should withstand the blow.

What happened

Shares of Incyte (INCY -0.50%) fell over 16% last month, according to data provided by S&P Global Market Intelligence. On the first trading day of the year, the company reported disappointing results from a phase 3 trial investigating the combination of itacitinib and corticosteroids as a treatment for treatment-naive acute graft-versus-host disease (GVHD). The drug candidate didn't meet its primary or secondary end points. 

While investors took the news pretty hard, Incyte followed up the disappointing news with several positive developments in January. The company signed a collaboration license agreement with MorphoSys for a novel monoclonal antibody, and announced positive outcomes in three separate studies for two unique drug candidates in atopic dermatitis. Despite the progress, the pharma stock lost ground as the month progressed. 

A declining pink arrow crashing through the x-axis on a chart.

Image source: Getty Images.

So what

Incyte has a relatively deep pipeline. The two largest and nearest opportunities are in GVHD and skin diseases. While the failure of itacitinib certainly reduces the potential in GVHD, a little nuance can go a long way.

Itacitinib was being studied as a treatment for steroid-naive GVHD, meaning individuals who had never been given corticosteroids. But Incyte is also studying Jakafi as a treatment for steroid-refractory GVHD, meaning individuals who aren't responding to corticosteroids.

The total opportunity in GVHD could generate peak annual sales of $925 million, according to SVB Leerink analyst Andrew Berens. It's not immediately clear how the discontinuation of itacitinib's development will affect that estimate, but the entire opportunity isn't lost. 

Meanwhile, the opportunity in skin diseases could be even larger. Morningstar analyst Karen Andersen projects that ruxolitinib cream could generate peak annual sales of $1 billion if approved in both atopic dermatitis and vitiligo. Yet, when Incyte announced positive phase 2 results for the drug candidate in atopic dermatitis in January, shares didn't even budge. 

Now what

Given Incyte's history of late-stage drug candidate failures, it's easy to see why investors were so disappointed by the itacitinib results in GVHD. But that may not be a fair assessment of the potential of the company's pipeline. If Jakafi and ruxolitinib cream continue to impress in steroid-refractory GVHD and skin diseases, respectively, then the stock's tumble in January will hardly be remembered.

Maxx Chatsko has no position in any of the stocks mentioned. The Motley Fool recommends Incyte. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Incyte Corporation Stock Quote
Incyte Corporation
$73.76 (-0.50%) $0.37
MorphoSys AG Stock Quote
MorphoSys AG
$5.83 (0.69%) $0.04

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 08/12/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.